Tag Archive for: mRNA-4157/V940

A combination of Merck’s blockbuster cancer drug Keytruda and an mRNA vaccine from Moderna has demonstrated positive results at the three-year stage in a Phase IIb study of patients with resected high-risk melanoma following complete resection.

Moderna entered into a collaboration/licensing agreement Thursday with oncology-focused CytomX to discover and develop conditionally activated mRNA therapies for cancer.